Armstrong AW, Puig L, Joshi A, et al. - In order to find out the relatively short-term and long-term efficacy of biologics and oral agents for the treatment of moderate to severe psoriasis, researchers performed a systematic literature review on December 4, 2017, and updated on September 17, 2018, including Embase, MEDLINE, and Cochrane Central Register databases. Sixty trials meeting all inclusion criteria were enrolled. The results showed that the highest PASI 90 rates were seen with risankizumab-rzaa, brodalumab, ixekizumab, and guselkumab at weeks 10 to 16. It was noted that the treatments with the highest PASI 90 rates were risankizumab-rzaa, guselkumab, brodalumab, and ixekizumab at weeks 44 to 60. This research gives an evaluation of the comparative efficacy among treatments for moderate to severe plaque psoriasis. The study found that, in both short-term and long-term therapy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were correlated with the highest PASI response rates.